Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 5,729

Document Document Title
WO/2007/039110A2
The invention relates to compounds according to formula (I) or formula (II), wherein R is H or (CHOH)nCH2OH (n= 0, 1 or 2), Sp is -CH-, -CHOH-, -(CH2)n-, -(CH=CH)n-, -(CH=CH-CH2)n,-, -(CH2)n-X-(CH2)o-, -(CH2-X)n-(CH2)o-, -(CH2)n-C(=X)-(C...  
WO2006129036B1
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2007/034909A1
Disclosed is a (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative which is useful as an intermediate for a pharmaceutical. A (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative or a salt thereof can be produced by a process compri...  
WO/2007/032362A1
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as...  
WO/2007/027599A1
This invention provides compounds of Formula (I) having the structure where R1, R2, R3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (I...  
WO/2007/015412A1
Disclosed is an organic electroluminescent device (organic EL device) of simple structure which is improved in luminous efficiency and sufficiently secured in driving stability. Also disclosed is a heterocyclic compound used for such an ...  
WO/2007/013201A1
A zinc fluorescent probe that excels in water solubility, enabling observing with high sensitivity of any change of intracellular zinc ion level ratiometrically with the use of a single excited wavelength; a process for producing the sam...  
WO/2007/010514A2
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...  
WO/2007/000383A1
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.  
WO/2006/134955A1
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...  
WO/2006/129736A1
It is intended to provide an industrially advantageous process for producing a cyclic ester, an industrially advantageous process for producing a cyclic oxyester which is a raw material of poly(hydroxyalkyloxyacetic acid ester), and an i...  
WO/2006/123726A1
A pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) vitamin D or a vitamin D derivative or a pharmacologically acceptable salt thereof; a therapeutic a...  
WO/2006/124899A2
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/121095A1
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...  
WO/2006/120755A1
Provided is a process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid more efficiently and industrially advantageously. The process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid repre...  
WO/2006/117611A1
The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1 -4 alkylene and B a C3-4...  
WO/2006/116158A1
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of...  
WO/2006/114432A2
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...  
WO/2006/110221A1
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...  
WO/2006/106241A1
The invention relates to a compound of formula (I) in which: R1, R2, R3, R4, while being identical or different, each represent an atom or group selected among H, halogen, alkyl, alkoxy, phenyl and cyano; X represents a bond, an oxygen a...  
WO/2006/103527A1
The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical...  
WO/2006/102760A1
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.  
WO/2006/098308A1
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...  
WO/2006/095020A1
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.  
WO/2006/092623A1
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group -(CH2)...  
WO/2006/085108A1
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...  
WO/2006/081332A1
The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower...  
WO/2006/081276A1
Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.  
WO/2006/072189A2
Described are substituted spiro[bornyl-2,4'-(1,3-dioxanes)], a method for their production and fragrance compositions comprising them.  
WO/2006/069656A1
The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as ...  
WO/2006/067466A2
The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the f...  
WO/2006/064611A1
ABSTRACT Disclosed is a process for purifying a hydroxycarboxylic acid, comprising: a crystallization step of subjecting a hydroxycarboxylic acid aqueous solution to crystallization for purification, a separation step of separating a hyd...  
WO/2006/062110A1
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...  
WO/2006/061372A2
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention...  
WO/2006/062093A1
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...  
WO/2006/058648A2
The present invention relates to compounds of Formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and...  
WO/2006/050212A1
The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of...  
WO/2006/048620A2
Liquid crystal compounds of Formula (I) for use in liquid crystal devices contains a dioxatetralin unit within the mesogenic liquid crystal core. The dioxatetralin unit may be located at any position within the mesogenic core of the liqu...  
WO2005030705A9
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...  
WO/2006/038606A1
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...  
WO/2006/034641A1
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...  
WO/2006/030892A1
The invention aims at providing a process for the production of NS-220 which is suitable for mass production on an industrial scale. The invention is constituted of (1) a process for the production of methyl cis-5-(4-chlorobutyl) -2-meth...  
WO/2006/028972A2
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...  
WO/2006/021806A1
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.  
WO/2006/022825A1
Various non-limiting embodiments disclosed herein related to photochromic materials comprising the reaction product of (a) at least one ring-opening cyclic monomer, and (b) a photochromic initiator. Other non-limiting embodiments related...  
WO/2006/021805A1
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.  
WO/2006/018855A1
Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them...  
WO/2006/018524A1
The invention relates to a novel method for the synthesis of 2,5-dioxane-1,4-diones having formula (I), comprising the oxidation of the ketone function of a cyclic compound having formula (II), wherein R1, R2, R3 and R4 independently rep...  
WO/2006/016708A1
Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases ten...  
WO/2006/012227A2
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...  

Matches 551 - 600 out of 5,729